G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX): 4 pipeline candidates · ~39 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
38.7 months
D/E 3.01 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for G1 Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$15.1M
Quarterly Burn
$5.3M
Runway
38.7 mo
Revenue
$16.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| cosela | Approved |
| cp12 | Phase 2 |
| tepezza | Approved |
| trilaciclib | Phase 3 |
Frequently asked questions
How many drug candidates are in G1 Therapeutics, Inc.'s pipeline?
G1 Therapeutics, Inc. (GTHX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is G1 Therapeutics, Inc.'s lead drug candidate?
G1 Therapeutics, Inc.'s most advanced tracked candidate is cosela (Approved) for Extensive-stage small cell lung cancer (ES-SCLC).
What is G1 Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, G1 Therapeutics, Inc. has approximately 38.7 months of cash runway.
Who is the CEO of G1 Therapeutics, Inc.?
John E. Bailey, Jr. is the chief executive officer of G1 Therapeutics, Inc. (GTHX).
Get the full picture on G1 Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.